Involvement of IL-33 in the Pathophysiology of Systemic Lupus Erythematosus: Review

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Mar 25

PMID 35328556

Authors

Julie Sarrand

Muhammad Soyfoo

Affiliations

Soon will be listed here.

Abstract

IL-33 is a newly discovered cytokine displaying pleiotropic localizations and functions. More specifically, it also functions as an alarmin, following its release from cells undergoing cell death or necrosis, to alert the innate immune system. The role of IL-33 has been underlined in several inflammatory and autoimmune diseases including systemic lupus erythematosus (SLE). The expressions of IL-33 as well as its receptor, ST2, are significantly upregulated in SLE patients and in patients with lupus nephritis. This review discusses the involvement of IL-33 in the pathology of SLE.

Citing Articles

Intricating connections: the role of ferroptosis in systemic lupus erythematosus.

Zhao G, Li X, Zhang Y, Wang X, Deng L, Xu J Front Immunol. 2025; 16:1534926.

PMID: 39967676 PMC: 11832682. DOI: 10.3389/fimmu.2025.1534926.

Tissue Kallikrein-1 Suppresses Type I Interferon Responses and Reduces Depressive-Like Behavior in the MRL/lpr Lupus-Prone Mouse Model.

Bhoj P, Nocito C, Togre N, Winfield M, Lubinsky C, Khan S Int J Mol Sci. 2024; 25(18).

PMID: 39337564 PMC: 11432477. DOI: 10.3390/ijms251810080.

ST2 levels and neurodegenerative diseases: is this a significant relation?.

Arora H, Javed B, Kutikuppala L, Chaurasia M, Khullar K, Kannan S Ann Med Surg (Lond). 2024; 86(5):2812-2817.

PMID: 38694387 PMC: 11060292. DOI: 10.1097/MS9.0000000000001939.

Analytical performances of a new rapid assay of soluble ST2 for cardiac and inflammatory diseases and establishment of the reference intervals for children and adolescence in China.

Ye Z, Chen C, Chen S, Xu M, Xu J Pract Lab Med. 2023; 36:e00321.

PMID: 37649538 PMC: 10462660. DOI: 10.1016/j.plabm.2023.e00321.

The Role of IL-33/ST2 in COPD and Its Future as an Antibody Therapy.

Riera-Martinez L, Canaves-Gomez L, Iglesias A, Martin-Medina A, Cosio B Int J Mol Sci. 2023; 24(10).

PMID: 37240045 PMC: 10217986. DOI: 10.3390/ijms24108702.

References

Rahman A, Isenberg D . Systemic lupus erythematosus. N Engl J Med. 2008; 358(9):929-39. DOI: 10.1056/NEJMra071297. View

Kuchler A, Pollheimer J, Balogh J, Sponheim J, Manley L, Sorensen D . Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol. 2008; 173(4):1229-42. PMC: 2543089. DOI: 10.2353/ajpath.2008.080014. View

Xu D, Chan W, Leung B, Huang F, Wheeler R, Piedrafita D . Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med. 1998; 187(5):787-94. PMC: 2212173. DOI: 10.1084/jem.187.5.787. View

Baekkevold E, Roussigne M, Yamanaka T, Johansen F, Jahnsen F, Amalric F . Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol. 2003; 163(1):69-79. PMC: 1868188. DOI: 10.1016/S0002-9440(10)63631-0. View

Werwitzke S, Trick D, Sondermann P, Kamino K, Schlegelberger B, Kniesch K . Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32). Ann Rheum Dis. 2007; 67(2):154-61. DOI: 10.1136/ard.2006.068981. View

Lott J, Sumpter T, Turnquist H . New dog and new tricks: evolving roles for IL-33 in type 2 immunity. J Leukoc Biol. 2015; 97(6):1037-48. DOI: 10.1189/jlb.3RI1214-595R. View

Palmer G, Lipsky B, Smithgall M, Meininger D, Siu S, Talabot-Ayer D . The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine. 2008; 42(3):358-64. DOI: 10.1016/j.cyto.2008.03.008. View

Guo J, Xiang Y, Peng Y, Huang H, Lan Y, Wei Y . The association of novel IL-33 polymorphisms with sIL-33 and risk of systemic lupus erythematosus. Mol Immunol. 2016; 77:1-7. DOI: 10.1016/j.molimm.2016.07.001. View

Neill D, Wong S, Bellosi A, Flynn R, Daly M, Langford T . Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010; 464(7293):1367-70. PMC: 2862165. DOI: 10.1038/nature08900. View

10.

Smithgall M, Comeau M, Yoon B, Kaufman D, Armitage R, Smith D . IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008; 20(8):1019-30. DOI: 10.1093/intimm/dxn060. View

11.

Zhan Y, Cheng L, Wu B, Ji L, Chen P, Li F . Interleukin (IL)-1 family cytokines could differentiate primary immune thrombocytopenia from systemic lupus erythematosus-associated thrombocytopenia. Ann Transl Med. 2021; 9(3):222. PMC: 7940935. DOI: 10.21037/atm-20-4729. View

12.

Dorner T, Furie R . Novel paradigms in systemic lupus erythematosus. Lancet. 2019; 393(10188):2344-2358. DOI: 10.1016/S0140-6736(19)30546-X. View

13.

Chinthrajah S, Cao S, Liu C, Lyu S, Sindher S, Long A . Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy. JCI Insight. 2019; 4(22). PMC: 6948865. DOI: 10.1172/jci.insight.131347. View

14.

Miller A, Xu D, Asquith D, Denby L, Li Y, Sattar N . IL-33 reduces the development of atherosclerosis. J Exp Med. 2008; 205(2):339-46. PMC: 2271006. DOI: 10.1084/jem.20071868. View

15.

Hayakawa H, Hayakawa M, Kume A, Tominaga S . Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. 2007; 282(36):26369-80. DOI: 10.1074/jbc.M704916200. View

16.

Stremska M, Dai C, Venkatadri R, Wang H, Sabapathy V, Kumar G . IL233, an IL-2-IL-33 hybrid cytokine induces prolonged remission of mouse lupus nephritis by targeting Treg cells as a single therapeutic agent. J Autoimmun. 2019; 102:133-141. PMC: 6642024. DOI: 10.1016/j.jaut.2019.05.005. View

17.

Koshy M, Berger D, Crow M . Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest. 1996; 98(3):826-37. PMC: 507493. DOI: 10.1172/JCI118855. View

18.

Cayrol C, Girard J . IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014; 31:31-7. DOI: 10.1016/j.coi.2014.09.004. View

19.

Xing Q, Wang B, Su H, Cui J, Li J . Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatol Int. 2011; 32(4):949-58. DOI: 10.1007/s00296-010-1771-0. View

20.

Allakhverdi Z, Smith D, Comeau M, Delespesse G . Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol. 2007; 179(4):2051-4. DOI: 10.4049/jimmunol.179.4.2051. View